Portal de Periódicos da CAPES

Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period

2002; BMJ; Volume: 61; Issue: 2 Linguagem: Inglês

10.1136/ard.61.2.171

1468-2060

D Kietz,

Inflammasome and immune disorders

To analyse the treatment response to etanercept in patients with polyarticular course juvenile idiopathic arthritis (JIA).22 patients with polyarticular course JIA (19 females, three males; mean age 13.9 years; mean disease duration 6.3 years; 15 with polyarticular onset, seven with systemic onset, one with residual systemic activity; eight rheumatoid factor positive; eight with erosive disease) were treated with etanercept for up to 24 months. Etanercept was given subcutaneously at 0.4 mg/kg twice a week. Treatment response was ascertained in an open prospective study.All patients showed impressive clinical improvement, with a decrease in swollen joint count by an average of 10.1 joints (mean of 49% decrease), a decrease in tender joint count by 9.3 joints (mean of 94%), and decrease in total joint count by 11.2 joints (mean of 48%). Duration of morning stiffness decreased to less than 10 minutes. Furthermore, haemoglobin concentration increased on average by 14 g/l (mean of 15.3%) and packed cell volume increased by 0.035 (mean increase of 12%), and erythrocyte sedimentation rate decreased on average by 42.8 mm/1st h (mean decrease of 64%). No major side effects were noted.Etanercept continues to be clinically effective and well tolerated in patients with polyarticular course JIA over a two year period.